HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Type 4 Cyclic Nucleotide Phosphodiesterases

Subscribe to New Research on Type 4 Cyclic Nucleotide Phosphodiesterases

A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes.

Also Known As:

Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterase PDE4 Family; Cyclic Nucleotide Phosphodiesterases, Type 4A; Cyclic Nucleotide Phosphodiesterases, Type 4A5; Cyclic Nucleotide Phosphodiesterases, Type 4B; Cyclic Nucleotide Phosphodiesterases, Type 4C; Cyclic Nucleotide Phosphodiesterases, Type 4D; Cyclic Nucleotide Phosphodiesterases, Type 4D3; PDE4 Phosphodiesterases; PDE4D3 Phosphodiesterase; Phosphodiesterase 4; Phosphodiesterase 4A; Phosphodiesterase 4B; Phosphodiesterase 4C; Phosphodiesterase 4D; Phosphodiesterase IV; Phosphodiesterase-4; Type 4 Cyclic Nucleotide Phosphodiesterase; cAMP-Specific Phosphodiesterase 4A5; Phosphodiesterase 4A5, cAMP-Specific; Phosphodiesterase, PDE4D3; Phosphodiesterases, PDE4; cAMP Specific Phosphodiesterase 4A5

Networked: 481 relevant articles (30 outcomes, 77 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rabe, Klaus F: 11 articles (01/2014 - 02/2002)
2.	Giembycz, Mark A: 7 articles (01/2015 - 01/2005)
3.	Calverley, Peter M A: 7 articles (01/2014 - 01/2007)
4.	Lahu, Gezim: 7 articles (11/2013 - 08/2008)
5.	Bredenbröker, Dirk: 6 articles (01/2014 - 08/2005)
6.	Bäumer, Wolfgang: 6 articles (01/2012 - 06/2002)
7.	Houslay, Miles D: 6 articles (10/2009 - 11/2005)
8.	Kietzmann, Manfred: 6 articles (04/2007 - 06/2002)
9.	Hu, ChiaChi: 5 articles (07/2015 - 08/2012)
10.	Zhang, Han-Ting: 5 articles (01/2015 - 08/2004)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 06/01/2002 - "While most of these drugs are still in preclinical evaluation, some recent phase II-III clinical trials have shown the beneficial effects of a new class of anti-inflammatory compounds, the phosphodiesterase-4 (PDE-4) inhibitors, in patients with COPD. " 08/01/2015 - "Alternative strategies to treatment including phosphodiesterase-4 inhibition and long-term antibiotic treatment have become reasonable alternatives to more established approaches, at least in terms of preventing COPD exacerbations. " 10/01/2013 - "Inhibition of phosphodiesterase 4 (PDE4) represents an approach to anti-inflammatory therapy in chronic obstructive pulmonary disease (COPD). " 01/01/2011 - "[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors]." 02/01/2010 - "Zl-n-91, a selective phosphodiesterase 4 inhibitor, suppresses inflammatory response in a COPD-like rat model."
2.	Asthma (Bronchial Asthma) 08/01/1998 - "Whether orally active safe phosphodiesterase 4 isoenzyme inhibitors will be useful in the treatment of asthma remains to be established." 04/01/2014 - "Compounds 1, 2, 5, and 8 showed inhibitory activities against phosphodiesterase-4 (PDE4), a therapeutic target of asthma, with IC50 values ranging from 2.57 to 8.94 μM. " 01/01/2014 - "The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma." 05/01/2012 - "Phosphodiesterase-4 (PDE4) has been identified to be a promising target for treatment of asthma. " 12/01/2010 - "Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma."
3.	Atopic Dermatitis (Atopic Eczema) 07/01/2014 - "The safety and efficacy of topical E6005, a novel phosphodiesterase 4 inhibitor, in Japanese adults with atopic dermatitis were evaluated. " 08/14/1999 - "Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis." 07/01/2014 - "Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial." 07/01/2013 - "Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model." 10/01/2015 - "A novel approach for treating atopic dermatitis (AD) is the inhibition of phosphodiesterase 4 (PDE4), an enzyme involved in the proinflammatory cascade. "
4.	Inflammation 11/01/2015 - "In chronic inflammation, prevention of cAMP degradation by phosphodiesterase-4 (PDE4) inhibition can be anti-inflammatory therapy. " 04/07/2015 - "Phosphodiesterase 4B (PDE4B) plays a key role in regulating inflammation. " 06/01/2012 - "Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation." 01/01/2012 - "Inhibitors of phosphodiesterase 4 (PDE4) are new anti-inflammatory drugs which cause cAMP accumulation in the cell and inhibit numerous stages of allergic inflammation. " 01/01/2012 - "Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation."
5.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2015 - "Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis." 06/01/2013 - "Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases." 01/01/2016 - "In the phase III double-blind Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in moderate to severe psoriasis. " 01/01/2016 - "Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)." 07/01/2015 - "Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)."

Related Drugs and Biologics

1.	Roflumilast
2.	Phosphodiesterase 4 Inhibitors
3.	apremilast
4.	Rolipram
5.	Anti-Inflammatory Agents (Anti-Inflammatories)
6.	SCH 351591
7.	5-Lipoxygenase-Activating Proteins
8.	Dexamethasone (Maxidex)
9.	LASSBIO596
10.	Smoke

Related Therapies and Procedures

1.	Therapeutics
2.	Transplants (Transplant)
3.	Ligation
4.	Airway Management
5.	Homologous Transplantation (Allograft)